IDWeek 2021
AWG Member Company Participation at IDWeek 2021
10 AWG member companies will present data from their clinical and research programs at the virtual IDWeek 2021 held September 29 – October 3, with a total of 23 posters and three oral abstracts.
IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP) that brings together infectious disease professionals to present and discuss the latest approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases.
A1. Novel Agents
Session: Novel Antimicrobial Agents
Oral Abstract
Venatorx Pharmaceuticals :
- 133 – ARGONAUT-III: Susceptibility of Carbapenem-resistant Klebsiellae to Cefepime-Taniborbactam
A1. Novel Agents
Poster Session: Novel Agents
Summit Therapeutics:
- 1052 – Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile
Qpex Biopharma:
- 1053 – The β-Lactamase Inhibitor QPX7728 Restores the Activity of β-Lactam Agents against Contemporary Extended-Spectrum b-lactamase (ESBL)-Producing and Carbapenem-Resistant Enterobacterales (CRE) Isolates, Including Isolates Producing Metallo-b-lactamases
Venatorx Pharmaceuticals:
- 1055 – ARGONAUT-IV: Susceptibility of Carbapenem-resistant Klebsiellae to Ceftibuten/VNRX-5236
- 1063 – ARGONAUT-V: Susceptibility of multidrug-resistant (MDR) Pseudomonas aeruginosa to Cefepime-Taniborbactam
Iterum Therapeutics
- 1072 – In Vitro Antibacterial Susceptibility Testing of Sulopenem Against Category A and B Bio-threat Bacterial Pathogens
Entasis Therapeutics:
- 1073 – Sulbactam-durlobactam has potent activity against multidrug-resistant Acinetobacter baumannii clinical isolates from Thai patients with chronic infections
Cidara Therapeutics:
- 1076 – Activity of Rezafungin and Comparator Antifungal Agents Tested Against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019-2020)
Paratek Pharmaceuticals:
- 1082 – Real-World Experience with Omadacycline for Nontuberculous Mycobacterial Infections: A Multicenter Evaluation
A3. Resistance Mechanisms
Poster Session: Resistance Mechanisms
Venatorx Pharmaceuticals:
- 1286 – Taniborbactam Inhibits Cefepime-Hydrolyzing Variants of Pseudomonas-derived Cephalosporinase (PDC)
A4. Treatment of antimicrobial resistant infections
Session: What’s New in Antimicrobial Resistance
Oral Abstract
Venatorx Pharmaceuticals:
- 203 – Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) against Pseudomonas aeruginosa from a Global 2018-2020 Surveillance Collection
A4. Treatment of antimicrobial resistant infections
Poster Session: Resistance Mechanisms
Venatorx Pharmaceuticals:
- 1253 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Clinical Isolates of Enterobacterales from 2018-2020 Global Surveillance
- 1293 – In vitro Activity of Ceftibuten in Combination with VNRX-5236 against Clinical Isolates of Enterobacterales from Urinary Tract Infections Collected in 2018-2020
A6. New Drug Development
Poster Session: New Drug Development
Paratek Pharmaceuticals:
- 1037 – Efficacy of Germinants and Omadacycline for Preventing Clostridioides difficile Relapse in a Murine Model
C3. Skin and Soft Tissue
Poster Session: Skin and Soft Tissue
Paratek Pharmaceuticals:
- 1372 – Comparison of Healthcare Resource Utilization (HRU) Among Adult Patients Treated with Omadacycline (OMC) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) or Community-Acquired Bacterial Pneumonia (CABP) in the 30 Day Pre- and Post-OMC Prescription (Rx)
C5. Respiratory Infections – Bacterial
Poster Session: Respiratory Infections – Bacterial
Nabriva Therapeutics:
- 1320 – In Vitro Activity of Lefamulin against Staphylococcus aureus isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis
C6. Enteric Infection
Poster Session: Enteric Infection
Acurx Pharmaceuticals:
- 701 – An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS) Antibiotic, for Patients with Clostridioides difficile Infection
Session D1. Diagnostics: Bacteriology/mycobacteriology
Poster Session: Diagnostics: Bacteriology/mycobacteriology
Venatorx Pharmaceuticals:
- 642 – Facility reported vs. CLSI MIC breakpoint comparison of Carbapenem non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A multicenter evaluation
M1. Clinical studies of fungal infections
Session: New Findings in Medical Mycology
Oral Abstract
SCYNEXIS
- 123 – Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
M1. Clinical studies of fungal infections
Poster Session: Medical Mycology
Cidara Therapeutics:
- 982 – Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
SCYNEXIS:
- 983 – Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI)
- 992 – Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI)
N8. Health Care-Associated Infections: C. difficile
Poster Session: HAI: C. difficile
Paratek Pharmaceuticals:
- 767 – Incidence of C. difficile infection (CDI) Cases by CDI-Standardized Infection Ratio (SIR) Among Centers for Medicare & Medicaid Services (CMS)-Participating Short-Term Acute Care Hospitals (ACH) Post Implementation of the Hospital-Acquired Condition Reduction Program (HAC-RP)
N10. Healthcare-Associated Infections: Gram-Negatives (MDR-GNR)
Poster Session: HAI: Gram-negatives (MDR-GNR)
Venatorx Pharmaceuticals:
- 786 – Facility reported vs. CLSI MIC breakpoint comparison of Carbapenem non-susceptible (Carb NS) Pseudomonas aeruginosa (PSA) from 2016-2019: A multicenter evaluation
O. Public Health
Poster Session: Public Health
Paratek Pharmaceuticals:
- 1208 – Omadacycline in Vitro Activity Against Bacillus Anthracis
S6. Antibiotic Stewardship: Trends in Antimicrobial Prescribing
Poster Session: Antimicrobial Stewardship: Trends in Antimicrobial Prescribing
Cidara Therapeutics:
- 157 – A Multicenter, Mixed-Method Evaluation of Delayed Hospital Discharge in Patients with Invasive Candidiasis Receiving Echinocandins